Safety, Tolerability, and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four
weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic
melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on
histological remission of cutaneous metastatic melanoma and induction of apoptotic
biomarkers.